基石藥業(02616.HK)治療胃癌藥物臨牀研究達到主要終點

You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.

Hong Kong

Open Account

基石藥業(02616.HK)治療胃癌藥物臨牀研究達到主要終點

阿思達克 11-11 08:55

基石藥業－B(02616.HK)公佈，舒格利單抗注射液聯合化療一線治療無法手術切除的局部晚期或轉移性胃/胃食管結合部腺癌的GEMSTONE-303研究達到主要終點之一：無進展生存期(PFS)。舒格利單抗聯合化療作爲局部晚期胃/胃食管結合部腺癌的一線治療可顯着改善PFS，將疾病進展或死亡風險降低34%；總生存期(OS)呈現明顯獲益的趨勢。在所有預設亞組中均觀察到臨牀獲益。舒格利單抗成爲全球首個在胃/胃食管結合部腺癌III期研究中取得積極結果的PD-L1單抗，並已在四項註冊性臨牀研究中取得積極結果。

基石药业-B(02616.HK)

Relevant Stocks

基石药业-B(02616.HK)

Customer Service Hotline︰+852 3018 4526

Email︰cs@usmarthk.com

Address︰26/F, 2606, 308 Des Voeux Road Central, Sheung Wan, Hong Kong

WhatsApp︰+852 5989 2641

Join the Community：

uSmart Securities Limited

is a licensed corporation approved by the Hong Kong SFC (CE number: BJA907), provides securities trading services and is subject to its supervision.

Market News

基石藥業(02616.HK)治療胃癌藥物臨牀研究達到主要終點

Services

About Us

Agreement Statement